Michael Partridge | Vertex Pharmaceuticals, Inc. |
Jeffrey M. Leiden, M.D., Ph.D. | Vertex Pharmaceuticals, Inc. |
Ian F. Smith | Vertex Pharmaceuticals, Inc. |
Stuart A. Arbuckle | Vertex Pharmaceuticals, Inc. |
Reshma Kewalramani | Vertex Pharmaceuticals, Inc. |
Philip Nadeau | Cowen & Co. LLC |
Robyn Karnauskas | Citigroup Global Markets, Inc. |
Jeff Hung | Morgan Stanley & Co. LLC |
Gavin Scott | Goldman Sachs & Co. LLC |
Andrew Tsai | Jefferies LLC |
Timur Ivannikov | Raymond James & Associates, Inc. |
Geoffrey C. Porges | Leerink Partners LLC |
Brian Abrahams | RBC Capital Markets LLC |
Olivia Brayer | Barclays Capital, Inc. |
Carmen Augustine | JPMorgan Securities LLC |
Good day ladies and gentlemen, and welcome to the Vertex Pharmaceuticals Second Quarter 2018 Conference Call.
As a reminder, today's program may be recorded. I would now like to introduce your host for today's program, Michael Partridge, Vertex Pharmaceuticals, Inc. Please go ahead.
Thank you, and welcome to the Vertex second quarter 2018 conference call.